Edition:
United Kingdom

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.01USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
166,072
52-wk High
$2.17
52-wk Low
$0.74

Latest Key Developments (Source: Significant Developments)

Durect reports Q3 earnings per share of ‍$0.04​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Durect Corp :Durect Corporation announces third quarter 2017 financial results and provides corporate update.Q3 revenue $20.7 million.Q3 revenue view $3.7 million -- Thomson Reuters I/B/E/S.Quarterly earnings per share ‍$0.04​.  Full Article

Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint
Thursday, 19 Oct 2017 

Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​.Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance.  Full Article

Durect Corp qtrly loss per share $0.07
Monday, 1 Aug 2016 

Durect Corp : Durect corporation announces second quarter 2016 financial results and update of programs . Q2 revenue $3.2 million versus i/b/e/s view $3.7 million . Qtrly loss per share $0.07 .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Durect says PDUFA date for remoxy NDA of Sept 25 unchanged
Friday, 1 Jul 2016 

Durect Corp : Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged . An FDA advisory committee meeting for remoxy is not needed and no change to September 25, 2016 PDUFA date . Pain Therapeutics stated that FDA advised them that regulatory review of remoxy new drug application (NDA) remains active and on-going .Durect provides remoxy update.  Full Article

DURECT Corp announces pricing of public offering of common stock
Tuesday, 26 Apr 2016 

DURECT Corp:Pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public.Gross proceeds to DURECT from this offering are expected to be $15 million.Offering is expected to close on or about April 29.  Full Article

DURECT Corp announces positive Phase 1 Data for DUR-928
Wednesday, 6 Jan 2016 

DURECT Corp:Announces positive Phase 1 Data for DUR-928.Says DURECT is now positioned to commence patient trials in 2016 with DUR-928.DUR-928 was well-tolerated at all dose levels, with no treatment-related adverse events reported and plasma levels were dose proportional.  Full Article

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update